The Non-Invasive Prediction of Colorectal Neoplasia (NIPCON) Study 1995-2022: A Comparison of Guaiac-Based Fecal Occult Blood Test (FOBT) and an Anti-Adenoma Antibody, Adnab-9
Document Type
Article
Publication Date
12-8-2023
Publication Title
International Journal of Molecular Sciences
Abstract
Given the need to improve the sensitivity of non-invasive methods to detect colorectal neoplasia, particularly adenomas, we compared a fecal test using a monoclonal antibody (Mab) raised against constituents of colonic adenomas designated Adnab-9 (Adenoma Antibody 9), recognizing an N-linked 87 kDa glycoprotein, to gFOBT, which is shown to reduce CRC mortality. p87 immunohistochemistry testing is significantly more sensitive (OR 3.64[CI 2.37-5.58]) than gFOBT (guaiac-based fecal occult blood test) for adenomas (number), advanced adenomas (OR 4.21[CI 2.47-7.15]), or a combination of the two (OR 3.35[CI 2.47-4.53]). p87 immunohistochemistry shows regional Paneth cell (PC) expression mainly in the right-sided colon and is significantly reduced in the ceca of African Americans (
Volume
24
Issue
24
First Page
17257
Recommended Citation
Tobi M, Antaki F, Rambus MA, Yang YX, Kaplan D, Rodriguez R, et al. The non-invasive prediction of colorectal neoplasia (NIPCON) study 1995-2022: a comparison of guaiac-based fecal occult blood test (FOBT) and an anti-adenoma antibody, Adnab-9. Int J Mol Sci. 2023 Dec 8;24(24):17257. doi: 10.3390/ijms242417257. PMID: 38139086.
DOI
10.3390/ijms242417257
ISSN
1422-0067
PubMed ID
38139086